Patient Preference and Treatment Satisfaction With a Port Delivery System for Ranibizumab vs Intravitreal Injections in Patients With Neovascular Age-Related Macular Degeneration

Chang, Margaret; Kapre, Audrey; Kaufman, Derrick; Kardatzke, David R; Rabena, Melvin D.; Patel, Shienal; Bobbala, Ashwini; Gune, Shamika; Fung, Anne E.; Wallenstein, Gene V.

doi:10.1001/jamaophthalmol.2022.1091

Cited by 15 publications

(15 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of these patients (73.5%) strongly preferred the PDS. These findings support the hypothesis that PDS would prove convenient to patients and eventually improve compliance and results [ 92 ].…”

Section: Ranibizumab Portal Delivery Systemsupporting

confidence: 85%

Current and Novel Therapeutic Approaches for Treatment of Neovascular Age-Related Macular Degeneration

2022

View full text Add to dashboard Cite

Age-related macular degeneration AMD is one of the leading causes of blindness in the elderly population. An advanced form of AMD known as neovascular AMD (nAMD) is implicated as the main attributor of visual loss among these patients. The hallmark feature of nAMD is the presence of neovascular structures known as choroidal neovascular membranes (CNVs), along with fluid exudation, hemorrhages, and subretinal fibrosis. These pathological changes eventually result in anatomical and visual loss. A type of proangiogenic factor known as vascular endothelial growth factor (VEGF) has been known to mediate the pathological process behind nAMD. Therefore, therapy has transitioned over the years from laser therapy that ablates the lesions to using Anti-VEGF to target the pathology directly. In this work, we provide an overview of current and emerging therapies for the treatment of nAMD. Currently approved Anti-VEGF agents include ranibizumab, aflibercept, and brolucizumab. Bevacizumab, also an Anti-VEGF agent, is used to manage nAMD even though this is an off-label use. While Anti-VEGF agents have provided a favorable prognosis for nAMD, they are associated with a substantial financial burden for patients and the healthcare system, due to their high cost as well as the need for frequent repeat treatments and visits. Emerging therapies and studies aim to extend the intervals between required treatments and introduce new treatment modalities that would improve patients’ compliance and provide superior results.

show abstract

Section: Ranibizumab Portal Delivery Systemsupporting

confidence: 85%

Current and Novel Therapeutic Approaches for Treatment of Neovascular Age-Related Macular Degeneration

2022

View full text Add to dashboard Cite

show abstract

“…Two clinical trials have been completed, one of these was a phase III clinical trial (NCT03677934) that emphasized treatment satisfaction and patient preference between PDS delivery of ranibizumab and intravitreal injection of the same. The results illustrated that treatment satisfaction was achieved in both interventions but nearly all patients preferred PDS over an intravitreal injection . Another completed study was a phase II clinical trial (NCT02510794) of PDS-mediated delivery ranibizumab for the treatment of neovascular age-related macular degeneration.…”

Section: Novel Approaches For the Delivery Of Protein And Peptidesmentioning

confidence: 99%

An Update on Strategies to Deliver Protein and Peptide Drugs to the Eye

Boddu,

Acharya,

Hala

et al. 2023

ACS Omega

View full text Add to dashboard Cite

In the past few decades, advancements in protein engineering, biotechnology, and structural biochemistry have resulted in the discovery of various techniques that enhanced the production yield of proteins, targetability, circulating half-life, product purity, and functionality of proteins and peptides. As a result, the utilization of proteins and peptides has increased in the treatment of many conditions, including ocular diseases. Ocular delivery of large molecules poses several challenges due to their high molecular weight, hydrophilicity, unstable nature, and poor permeation through cellular and enzymatic barriers. The use of novel strategies for delivering protein and peptides such as glycoengineering, PEGylation, Fc-fusion, chitosan nanoparticles, and liposomes have improved the efficacy, safety, and stability, which consequently expanded the therapeutic potential of proteins. This review article highlights various proteins and peptides that are useful in ocular disorders, challenges in their delivery to the eye, and strategies to enhance ocular bioavailability using novel delivery approaches. In addition, a few futuristic approaches that will assist in the ocular delivery of proteins and peptides were also discussed.

show abstract

“…Patients with nAMD treated by an RPDS with fixed 24-week refill-exchanges showed noninferiority to intravitreal injection of ranibizumab every 4 weeks [ 165 ]. A port delivery system would be a better option to lighten the treatment burden, as almost all patients treated with RPDS preferred the treatment to the classical protocol by intravitreal injection [ 166 ]. KSI-301 is a new intravitreal anti-vascular endothelial growth factor (VEGF) antibody biopolymer conjugate.…”

Section: Retinal Vein Occlusionmentioning

confidence: 99%

Risk Factors and Treatment Strategy for Retinal Vascular Occlusive Diseases

Terao

Fujino

Ahmed

2022

JCM

View full text Add to dashboard Cite

Retinal occlusive diseases are common diseases that can lead to visual impairment. Retinal artery occlusion and retinal vein occlusion are included in the clinical entity, but they have quite different pathophysiologies. Retinal artery occlusion is an emergent eye disorder. Retinal artery occlusion is mainly caused by thromboembolism, which frequently occurs in conjunction with life-threatening stroke and cardiovascular diseases. Therefore, prompt examinations and interventions for systemic vascular diseases are often necessary for these patients. Retinal vein occlusion is characterized by retinal hemorrhage and ischemia, which may impair visual function via several complications such as macular edema, macular ischemia, vitreous hemorrhage, and neovascular glaucoma. Even though anti-vascular endothelial growth factor therapy is the current established first-line of treatment for retinal vein occlusion, several clinical studies have been performed to identify better treatment protocols and new therapeutic options. In this review, we summarize the current findings and advances in knowledge regarding retinal occlusive diseases, particularly focusing on recent studies, in order to provide an update for a better understanding of its pathogenesis.

show abstract

Patient Preference and Treatment Satisfaction With a Port Delivery System for Ranibizumab vs Intravitreal Injections in Patients With Neovascular Age-Related Macular Degeneration

Cited by 15 publications

References 29 publications

Current and Novel Therapeutic Approaches for Treatment of Neovascular Age-Related Macular Degeneration

Current and Novel Therapeutic Approaches for Treatment of Neovascular Age-Related Macular Degeneration

An Update on Strategies to Deliver Protein and Peptide Drugs to the Eye

Risk Factors and Treatment Strategy for Retinal Vascular Occlusive Diseases

Contact Info

Product

Resources

About